"Novel cutting-edge technologies emerge at the conjunction of once separated spheres of research." Today, the tech revolution is taking place at the conjunction of AI, #machinelearning and #Biotechnology. Read on to learn more about this new frontier and how Nodes Advisors AG is supporting founders and startups in the space! What do you think will be the biggest impacts of these innovations? #artificialintelligence #innovation #ai #biology #founderstories #startups https://lnkd.in/dvgQBWc
Nodes Advisors AG
Wagniskapital- und Private-Equity-Auftraggeber
Zurich, Zurich 1.249 Follower:innen
A zurich-based Corporate finance firm committed to advancing Life Sciences through advisory and capital raise.
Info
A Zurich based advisory transaction firm that focuses on breakthrough and novel Life sciences, climate tech and emerging technologies. Our team is made up of entrepreneurs, engineers, researchers and venture capitalists who share a passion for accelerating the adoption of cutting edge technologies in the field of Life Sciences, climate tech and emerging technologies.
- Website
-
http://www.nodesadvisors.com
Externer Link zu Nodes Advisors AG
- Branche
- Wagniskapital- und Private-Equity-Auftraggeber
- Größe
- 11–50 Beschäftigte
- Hauptsitz
- Zurich, Zurich
- Art
- Privatunternehmen
- Gegründet
- 2018
- Spezialgebiete
- venture capital, entrepreneurship, startups, technology, investment, founders, corporate finance, investment banking, healthcare, biotech, life science, digital therapeutics, precision medicine, sell side, corporate advisory, switzerland, zurich, Europe, entrepreneurs, climate tech , energy tech und hedge fund
Orte
-
Primär
Wegbeschreibung
Claridenstrasse 34
Zurich, Zurich 8002, CH
Beschäftigte von Nodes Advisors AG
Updates
-
Nodes Advisors AG hat dies direkt geteilt
People should be talking about radiopharmaceuticals right now! Why? Amidst American elections, rising global geopolitical tensions, and high inflation rates, it may have been easy to miss the trend of funding steadily pouring into radiopharmaceuticals. Radionetics Oncology recently formed a strategic relationship with Eli Lilly for $140 million upfront and an exclusive right to acquire after an exercise period for $1 billion. Novartis picked up three separate deals evaluated at around $2 billion each this year in radiopharmaceuticals alone. This may feel incongruent with the market on a broader scale. The World Bank found in early 2024 that the global economy was set to have the worst half-decade performance in over 30 years. However, according to HSBC, biotechnology startups did extremely well in the first quarter of the year, with venture-backed biopharma companies raising as much as $6.8 billion (which is notably the largest amount raised since early 2022). That said, overall funding is still down since 2022, and the global economy slowdown has not revived the market or funding fervor. If anything, AI has been taking over the venture capital conversation, with U.S. venture capital funding surging to $55.6 billion in the second quarter, showing a 47% jump from the $37.8 billion in the first quarter, largely driven by big investments raised by Elon Musk and CoreWeave. But fundamentally, a pattern can be seen by big pharmaceutical companies pouring investments and acquiring radiopharmaceutical related technologies and manufacturing. So where does it all come from? Check our latest article for the answer!
The History of Radiopharmacy: Repackaging of an Old Tool
medium.com
-
People should be talking about radiopharmaceuticals right now! Why? Amidst American elections, rising global geopolitical tensions, and high inflation rates, it may have been easy to miss the trend of funding steadily pouring into radiopharmaceuticals. Radionetics Oncology recently formed a strategic relationship with Eli Lilly for $140 million upfront and an exclusive right to acquire after an exercise period for $1 billion. Novartis picked up three separate deals evaluated at around $2 billion each this year in radiopharmaceuticals alone. This may feel incongruent with the market on a broader scale. The World Bank found in early 2024 that the global economy was set to have the worst half-decade performance in over 30 years. However, according to HSBC, biotechnology startups did extremely well in the first quarter of the year, with venture-backed biopharma companies raising as much as $6.8 billion (which is notably the largest amount raised since early 2022). That said, overall funding is still down since 2022, and the global economy slowdown has not revived the market or funding fervor. If anything, AI has been taking over the venture capital conversation, with U.S. venture capital funding surging to $55.6 billion in the second quarter, showing a 47% jump from the $37.8 billion in the first quarter, largely driven by big investments raised by Elon Musk and CoreWeave. But fundamentally, a pattern can be seen by big pharmaceutical companies pouring investments and acquiring radiopharmaceutical related technologies and manufacturing. So where does it all come from? Check our latest article for the answer!
The History of Radiopharmacy: Repackaging of an Old Tool
medium.com
-
Congratulations to Remedium Bio on securing an investment from Wharton Alumni Angels! 🎉
Remedium receives investment from the Wharton Alumni Angels BOSTON, Apr 22, 2024 – Remedium Bio, the developer of the first adjustable dose gene therapy platform - Prometheus™, is pleased to announce an investment from the Wharton Alumni Angels (WAA). WAA is an active investment group focused on several business sectors including life sciences, and has made over 20 investments in early stage life science companies since its inception in 2019. WAA membership includes over 400 Wharton Business School Alumni. “Remedium is honored to welcome the Wharton Alumni Angels to our investor family,” said Frank Luppino, President and CEO of Remedium. “We are grateful for their recognition of the potential of our first-in-class adjustable dose gene therapy platform - Prometheus™, and its lead candidate, RMD1202, to transform the type 2 diabetes and obesity treatment landscape as well as other diseases currently treated with repeat therapeutic protein injections.” “Our decision to invest in Remedium stems from the potential for their technology to significantly impact patients' lives by bringing the benefits of gene therapy to prevalent diseases,” said Ellen Chang, President of the Wharton Alumni Angels. Contact Remedium: info@remedium-bio.com Source: Remedium Bio, Inc. #biotechnology #genetherapy #venturecapital #diabetes https://lnkd.in/fiq_sGE
Wharton Alumni Angels
whartonalumniangels.com
-
Nodes Advisors AG hat dies direkt geteilt
Congratulations to Remedium Bio on securing an investment from SeedFolio, propelling their revolutionary Prometheus™ gene therapy platform forward in the fight against Type 2 Diabetes and Obesity. We're proud to support Remedium Bio's innovative journey!
Remedium Bio receives investment from SeedFolio to advance lead asset BOSTON, Mar 21, 2024 - Remedium Bio is developing a first-in-class adjustable-dose gene therapy platform called Prometheus™, which is capable of replacing a broad range of multi-protein injection treatments with a single injection, dose adjustable, gene therapy. The treatment, which is administered by a subcutaneous injection, is highly safe, localized, durable, and costs a fraction of even current protein-based therapeutics. Unlike with therapeutic protein injections, Prometheus™ delivers stable, durable, and consistent protein expression, eliminating the concentration spikes that can limit the safety and efficacy of treatments delivered by repeat injection. The platform is able to deliver a broad range of proteins, from peptides to antibodies. The first Prometheus™ candidate delivers a GLP-1 receptor agonist and demonstrates weight loss, glycemic control, and insulin response superior to daily GLP-1 protein injections - with a potentially increased safety and tolerability profile. “SeedFolio’s investment is timely as we accelerate development of Prometheus™ platform in advance of our upcoming Series A financing round”, said Frank Luppino, President and CEO of Remedium. “The investment will support our ongoing work to advance our lead candidate RMD1202, a single injection GLP-1 RA treatment for Type 2 Diabetes and Obesity, to first-in-human studies”. “We invested due to the many potential applications of this novel gene-therapy delivery approach. Their first application could potentially leapfrog the bottlenecks found with current blockbusters like Wegovy and Mounjaro,” said Joe Gatto, Managing Director of SeedFolio. https://www.seedfolio.vc Contact: info@remedium-bio.com Source: Remedium Bio, Inc. #genetherapy #biotechnology #venturecapital #GLP1 #diabetes #obesity
seedfolio
seedfolio.vc
-
Congratulations to Remedium Bio on securing an investment from SeedFolio, propelling their revolutionary Prometheus™ gene therapy platform forward in the fight against Type 2 Diabetes and Obesity. We're proud to support Remedium Bio's innovative journey!
Remedium Bio receives investment from SeedFolio to advance lead asset BOSTON, Mar 21, 2024 - Remedium Bio is developing a first-in-class adjustable-dose gene therapy platform called Prometheus™, which is capable of replacing a broad range of multi-protein injection treatments with a single injection, dose adjustable, gene therapy. The treatment, which is administered by a subcutaneous injection, is highly safe, localized, durable, and costs a fraction of even current protein-based therapeutics. Unlike with therapeutic protein injections, Prometheus™ delivers stable, durable, and consistent protein expression, eliminating the concentration spikes that can limit the safety and efficacy of treatments delivered by repeat injection. The platform is able to deliver a broad range of proteins, from peptides to antibodies. The first Prometheus™ candidate delivers a GLP-1 receptor agonist and demonstrates weight loss, glycemic control, and insulin response superior to daily GLP-1 protein injections - with a potentially increased safety and tolerability profile. “SeedFolio’s investment is timely as we accelerate development of Prometheus™ platform in advance of our upcoming Series A financing round”, said Frank Luppino, President and CEO of Remedium. “The investment will support our ongoing work to advance our lead candidate RMD1202, a single injection GLP-1 RA treatment for Type 2 Diabetes and Obesity, to first-in-human studies”. “We invested due to the many potential applications of this novel gene-therapy delivery approach. Their first application could potentially leapfrog the bottlenecks found with current blockbusters like Wegovy and Mounjaro,” said Joe Gatto, Managing Director of SeedFolio. https://www.seedfolio.vc Contact: info@remedium-bio.com Source: Remedium Bio, Inc. #genetherapy #biotechnology #venturecapital #GLP1 #diabetes #obesity
seedfolio
seedfolio.vc